These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27582738)

  • 1. Biophysical and Biochemical Outcomes of Chlamydia pneumoniae Infection Promotes Pro-atherogenic Matrix Microenvironment.
    Evani SJ; Dallo SF; Ramasubramanian AK
    Front Microbiol; 2016; 7():1287. PubMed ID: 27582738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression.
    Kol A; Sukhova GK; Lichtman AH; Libby P
    Circulation; 1998 Jul; 98(4):300-7. PubMed ID: 9711934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shear stress upregulates IL-1β secretion by Chlamydia pneumoniae- infected monocytes.
    Cheeniyil A; Evani SJ; Dallo SF; Ramasubramanian AK
    Biotechnol Bioeng; 2015 Apr; 112(4):838-42. PubMed ID: 25336058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN) and gelatinases in human atherosclerosis infected with Chlamydia pneumoniae: the potential role of Chlamydia pneumoniae infection in the progression of atherosclerosis.
    Choi EY; Kim D; Hong BK; Kwon HM; Song YG; Byun KH; Park HY; Whang KC; Kim HS
    Exp Mol Med; 2002 Dec; 34(6):391-400. PubMed ID: 12526080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae.
    Kothe H; Dalhoff K; Rupp J; Müller A; Kreuzer J; Maass M; Katus HA
    Circulation; 2000 Apr; 101(15):1760-3. PubMed ID: 10769273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture.
    Schmidt R; Redecke V; Breitfeld Y; Wantia N; Miethke T; Massberg S; Fischel S; Neumann FJ; Schömig A; May AE
    Thromb Haemost; 2006 Jan; 95(1):151-8. PubMed ID: 16543974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial Chlamydia pneumoniae infection promotes oxidation of LDL.
    Dittrich R; Dragonas C; Mueller A; Maltaris T; Rupp J; Beckmann MW; Maass M
    Biochem Biophys Res Commun; 2004 Jun; 319(2):501-5. PubMed ID: 15178434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serologic and histopathologic study of Chlamydia pneumoniae infection in atherosclerosis: a possible pathogenetic mechanism of atherosclerosis induced by Chlamydia pneumoniae.
    Song YG; Kwon HM; Kim JM; Hong BK; Kim DS; Huh AJ; Chang KH; Kim HY; Kang TS; Lee BK; Choi DH; Jang YS; Kim HS
    Yonsei Med J; 2000 Jun; 41(3):319-27. PubMed ID: 10957885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlamydia pneumoniae infection promotes monocyte transendothelial migration by increasing vascular endothelial cell permeability via the tyrosine phosphorylation of VE-cadherin.
    Liu J; Miao G; Wang B; Zheng N; Ma L; Chen X; Wang G; Zhao X; Zhang L; Zhang L
    Biochem Biophys Res Commun; 2018 Mar; 497(2):742-748. PubMed ID: 29462613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biophysical regulation of Chlamydia pneumoniae-infected monocyte recruitment to atherosclerotic foci.
    Evani SJ; Ramasubramanian AK
    Sci Rep; 2016 Jan; 6():19058. PubMed ID: 26785849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro infection and pathogenesis of Chlamydia pneumoniae in endovascular cells.
    Quinn TC; Gaydos CA
    Am Heart J; 1999 Nov; 138(5 Pt 2):S507-11. PubMed ID: 10539860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae.
    Hu H; Pierce GN; Zhong G
    J Clin Invest; 1999 Mar; 103(5):747-53. PubMed ID: 10074493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection].
    Stille W; Dittmann R
    Herz; 1998 May; 23(3):185-92. PubMed ID: 9646100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways.
    Netea MG; Kullberg BJ; Galama JM; Stalenhoef AF; Dinarello CA; Van der Meer JW
    Eur J Immunol; 2002 Apr; 32(4):1188-95. PubMed ID: 11932927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.
    Li W; Gudipaty P; Li C; Henderson KK; Ramsey KH; Murthy AK
    Immunol Cell Biol; 2019 Jan; 97(1):85-91. PubMed ID: 30051926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells.
    Netea MG; Selzman CH; Kullberg BJ; Galama JM; Weinberg A; Stalenhoef AF; Van der Meer JW; Dinarello CA
    Eur J Immunol; 2000 Feb; 30(2):541-9. PubMed ID: 10671210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherogenetically relevant cells support continuous growth of Chlamydia pneumoniae.
    Maass M; Gieffers J; Solbach W
    Herz; 2000 Mar; 25(2):68-72. PubMed ID: 10829241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chlamydia pneumoniae infection in human monocytes.
    Airenne S; Surcel HM; Alakärppä H; Laitinen K; Paavonen J; Saikku P; Laurila A
    Infect Immun; 1999 Mar; 67(3):1445-9. PubMed ID: 10024593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role?
    Mahony JB; Coombes BK
    FEMS Microbiol Lett; 2001 Apr; 197(1):1-9. PubMed ID: 11287138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chlamydia pneumoniae and atherosclerosis: links to the disease process.
    Byrne GI; Kalayoglu MV
    Am Heart J; 1999 Nov; 138(5 Pt 2):S488-90. PubMed ID: 10539855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.